The generic name of Onivyde is irinotecan [1]. Onivyde is a liposomal formulation of irinotecan hydrochloride [2].
What is irinotecan used for?
Irinotecan is a topoisomerase I inhibitor used in the treatment of metastatic pancreatic cancer. It is typically administered in combination with other chemotherapy drugs, such as fluorouracil and leucovorin [2].
How does irinotecan work?
Irinotecan is a prodrug that is converted in the body to its active metabolite, SN-38. SN-38 inhibits topoisomerase I, an enzyme essential for DNA replication and repair. By inhibiting this enzyme, irinotecan leads to DNA damage and cell death, particularly in rapidly dividing cancer cells [3].
When does the patent for Onivyde expire?
Patent expiration dates can be complex and may vary for different patents covering a drug. Information on specific patent expiries for Onivyde can be found on resources like DrugPatentWatch.com [4].
Are there alternative treatments for pancreatic cancer?
Yes, other chemotherapy regimens are used to treat pancreatic cancer, including gemcitabine, nab-paclitaxel, and FOLFIRINOX (a combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin). The choice of treatment depends on the stage of the cancer, the patient's overall health, and other factors [5].